Under active development. Data is being added and corrected on an hourly basis.

← Back to Peptides
Macimorelin structure

Macimorelin

Growth Hormone
Approved Research
90%
Low Risk
1/5

Warnings

Diagnostic use only
CYP3A4 interactions
False negative possible with obesity

Contraindications

PregnancyBreastfeeding

Drug Interactions

CYP3A4 InhibitorsStrong CYP3A4 Inducers

Possible Side Effects

DysgeusiaDizzinessHeadacheFatigue

Legal & Regulatory

FDA Status FDA Approved
WADA Status Prohibited in Sport
Approved In USA, EU
Prescription Required

Pregnancy

Not Rated